1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Aurobindo Pharma
  6. News
  7. Summary
    AUROPHARMA   INE406A01037


Delayed NSE India Stock Exchange  -  07:25 2022-08-12 am EDT
593.45 INR   +3.08%
08/12AUROBINDO PHARMA : Newspaper Advertisements
08/12Aurobindo Pharma's Consolidated Profit Slides in Fiscal Q1; EPS Misses Estimates
08/11TRANSCRIPT : Aurobindo Pharma Limited, Q1 2023 Earnings Call, Aug 12, 2022
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

India shares close at over 2-week high as tech, metal stocks gain

06/27/2022 | 06:55am EDT

BENGALURU, June 27 (Reuters) - Indian shares joined a rally in global stock markets to close at a more than two-week high on Monday, led by technology and metal stocks, as easing oil prices tempered inflation fears.

The NSE Nifty 50 index rose 0.85% to 15,832.05, and the S&P BSE Sensex climbed 0.82% to 53,161.28, with both the indexes gaining for a third straight session.

"While the change in mood has come as a major relief, the optimism may remain for a few more sessions before the market turns volatile amid concerns over slowing global economy due to rate hikes and continuing foreign fund outflows," said Shrikant Chouhan, head of equity research (retail) at Kotak Securities.

Worries around inflation and policy have driven the benchmark indexes down around 4.5% each for the month so far, putting them on track for their worst month since the pandemic-hit March in 2020.

On Monday, the Nifty IT was the best performing sub-index in Mumbai, jumping 2.3% to its highest since June 10, boosted by a 2.8% rise in heavyweight Infosys.

The Nifty Metal index, which has fallen sharply this month, rose 1.5%.

Welspun Corp jumped 4.5% after the steel products maker said it received orders worth 6 billion rupees.

Shares of two- and three-wheeler maker Bajaj Auto gave up some of the early gains, settling 1.3% higher, as analysts said its 25 billion rupee ($319.23 million) open market share buyback announcement disappointed investors.

Aurobindo Pharma slipped 1% after the drugmaker said it received a warning letter from the Indian market regulator for not complying with disclosure regulations regarding an U.S. Food and Drug Administration's audit on its unit.

Food delivery firm Zomato slid 6.6%, after rising 3.1% in early trade, following a deal to buy local grocery-delivery startup Blinkit for 44.47 billion rupees ($567.94 million). ($1 = 78.3125 Indian rupees) (Reporting by Chris Thomas in Bengaluru; Editing by Vinay Dwivedi)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
AUROBINDO PHARMA 3.08% 593.45 Delayed Quote.-19.19%
BAJAJ AUTO LIMITED 0.11% 4038 End-of-day quote.24.27%
INFOSYS LIMITED -1.60% 1594.1 Delayed Quote.-15.56%
LONDON BRENT OIL -1.47% 97.84 Delayed Quote.27.42%
NIFTY 50 0.22% 17698.15 Delayed Quote.1.76%
NIFTY IT -0.86% 29885.9 Delayed Quote.-21.88%
SENSEX BSE30 0.22% 59462.78 Real-time Quote.2.08%
WELSPUN CORP LIMITED 1.66% 211.7 End-of-day quote.18.67%
WTI -2.31% 91.866 Delayed Quote.24.73%
ZOMATO LIMITED 6.65% 61.75 Delayed Quote.-55.06%
08/12AUROBINDO PHARMA : Newspaper Advertisements
08/12Aurobindo Pharma's Consolidated Profit Slides in Fiscal Q1; EPS Misses Estimates
08/11TRANSCRIPT : Aurobindo Pharma Limited, Q1 2023 Earnings Call, Aug 12, 2022
08/11AUROBINDO PHARMA : Earnings Presentation-Q1 FY 2022-23
08/11AUROBINDO PHARMA : Pr-q1 fy 2022-23
08/11Aurobindo Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, ..
08/09AUROBINDO PHARMA : National stock exchange of india limited
08/05Aurobindo Pharma Get VAI from US FDA for Manufacturing Facility in Hyderabad, India
08/02Aurobindo Pharma Gets Three Observations from US FDA After Inspection of Andhra Pradesh..
08/02Aurobindo Pharma Limited Informs Inspection At the Company's Unit Xi and Warning Letter..
More news
Analyst Recommendations on AUROBINDO PHARMA
More recommendations
Sales 2023 254 B 3 185 M 3 185 M
Net income 2023 27 180 M 341 M 341 M
Net cash 2023 27 299 M 343 M 343 M
P/E ratio 2023 12,8x
Yield 2023 0,72%
Capitalization 348 B 4 367 M 4 367 M
EV / Sales 2023 1,26x
EV / Sales 2024 1,14x
Nbr of Employees 15 431
Free-Float 49,3%
Duration : Period :
Aurobindo Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUROBINDO PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 31
Last Close Price 593,45 INR
Average target price 701,88 INR
Spread / Average Target 18,3%
EPS Revisions
Managers and Directors
Kambam Nithyananda Reddy Vice Chairman & Managing Director
Santhanam Subramanian Chief Financial Officer
Kannan Ragunathan Non-Executive Chairman
B. Adi Reddy Secretary & Compliance Officer
Avnit Bimal Singh Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-3.37%439 441
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-15.14%271 020
ABBVIE INC.5.32%251 211